$100.63 -2.25 (%) Incyte Corp - NASDAQ

Dec. 9, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Stock Indexes Extend Gains, But Big R&D Biotechs Dive

    Investors Business Daily | Dec. 7, 2016 | 14:04PM EST
  2. Market Reversal In Biotech But Healthcare Stocks Are Still Muddled

    TalkMarkets | Nov. 29, 2016 | 22:56PM EST
  3. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?

    TalkMarkets | Nov. 23, 2016 | 00:13AM EST
  4. Incyte Shares Jump After Gilead Misses With Myelofibrosis Competitor

    TalkMarkets | Nov. 16, 2016 | 21:30PM EST
  5. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  6. Zoetis Tops Q3 Earnings Estimates, Updates Outlook

    TalkMarkets | Nov. 2, 2016 | 11:14AM EST
  7. Novartis Tops Q3 Earnings, Misses Sales Estimates

    TalkMarkets | Oct. 25, 2016 | 12:47PM EST
  8. Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

    TalkMarkets | Oct. 12, 2016 | 11:14AM EST
  9. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  10. Morning Call For September 29, 2016

    TalkMarkets | Sep. 29, 2016 | 09:03AM EST
  11. Mid-Day Market Update: Dow Drops Over 300 Points; Cisco Shares Surge Following Strong Q2 Results

    Benzinga | Feb. 11, 2016 | 12:38PM EST
  12. Incyte Plummets After Stopping Trial Of Jakafi In Pancreatic Cancer

    IBD | Feb. 11, 2016 | 11:16AM EST
  13. Mid-Morning Market Update: Markets Open Lower; PepsiCo Posts In-Line Q4 Profit

    Benzinga | Feb. 11, 2016 | 09:48AM EST
  14. CTI-Baxalta Drug Withdrawn, Removing Potential Incyte Rival

    IBD | Feb. 10, 2016 | 13:50PM EST
  15. Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook

    Benzinga | Jan. 28, 2016 | 14:31PM EST
  16. Mid-Day Market Update: Facebook Surges On Strong Results; ServiceNow Shares Slip

    Benzinga | Jan. 28, 2016 | 12:00PM EST
  17. Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views

    Benzinga | Jan. 28, 2016 | 10:06AM EST
  18. Last-Hour Rally Erases Midday Losses As Indexes Close Mixed

    IBD | Jan. 19, 2016 | 16:49PM EST
  19. Benzinga's Top Initiations

    Benzinga | Jan. 5, 2016 | 09:54AM EST
  20. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD | Dec. 30, 2015 | 14:16PM EST
  21. Incyte Announces Two Phase 3 Studies Show Sustained Benefits of Jakafi in Patients with Myeloproliferative Neoplasms (MPNs)

    Benzinga | Dec. 5, 2015 | 10:22AM EST
  22. Incyte Announces Phase 3 RESPONSE-2 Study of Jakafi Meets Primary Endpoint

    Benzinga | Dec. 5, 2015 | 10:20AM EST
  23. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD | Dec. 1, 2015 | 15:31PM EST
  24. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  25. Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA

    Benzinga | Nov. 7, 2015 | 20:04PM EST
  26. The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings

    GuruFocus | Nov. 4, 2015 | 15:42PM EST
  27. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data

    Benzinga | Oct. 27, 2015 | 12:20PM EST
  28. Amazon Among Ken Fisher's Best Performing Stocks

    GuruFocus | Oct. 19, 2015 | 18:18PM EST
  29. Lilly-Incyte drug beats Humira

    IBD | Oct. 14, 2015 | 17:35PM EST
  30. Lilly-Incyte Drug Beats Humira In Arthritis Trial

    IBD | Oct. 14, 2015 | 10:12AM EST
  31. Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma

    Benzinga | Oct. 13, 2015 | 06:30AM EST
  32. Lilly Upgraded On Bullish Diabetes Outlook

    IBD | Oct. 9, 2015 | 11:11AM EST
  33. AbbVie Spurns Galapagos To Advance Own Arthritis Drug

    IBD | Sep. 25, 2015 | 11:51AM EST
  34. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga | Sep. 14, 2015 | 15:01PM EST
  35. Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210

    Benzinga | Sep. 2, 2015 | 04:01AM EST
  36. Benzinga's Top Initiations

    Benzinga | Aug. 13, 2015 | 08:31AM EST
  37. What Will Gilead Buy Next? 4 Possible Targets

    IBD | Jul. 15, 2015 | 15:44PM EST
  38. Celgene Hits High As Street Applauds Receptos Buyout

    IBD | Jul. 15, 2015 | 10:12AM EST
  39. Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

    Benzinga | Jun. 25, 2015 | 06:07AM EST
  40. Benzinga's Top Initiations

    Benzinga | May. 29, 2015 | 08:25AM EST
  41. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data

    Benzinga | May. 28, 2015 | 12:00PM EST
  42. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 15:31PM EST
  43. Incyte Describes Emerging Development Pipeline Related to Eleven Abstracts at AACR

    Benzinga | Apr. 17, 2015 | 06:39AM EST
  44. Morning Market Gainers

    Benzinga | Feb. 11, 2015 | 09:48AM EST
  45. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  46. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  47. 3 Biotech ETFs Rally On Merger News

    Benzinga | Dec. 8, 2014 | 17:43PM EST
  48. 5 Stock-Moving Medtech Events This December

    IBD | Nov. 28, 2014 | 14:18PM EST
  49. Incyte Building Blockbuster Drug One Disease At A Time

    IBD | Nov. 17, 2014 | 15:58PM EST
  50. 1 Biotech Beast Worth Tracking

    Benzinga | Nov. 12, 2014 | 12:08PM EST
Trading Center